摘要
血管紧张素转换酶（ACE）2是近年来新发现的一种单羧肽酶，是已知的第一个ACE同系物。ACE2催化血管紧张素（Ang）Ⅱ生成Ang（1-7），后者与Mas受体结合，从而启动对AngⅡ信号级联反应的抑制作用。ACE2能够通过增加胰岛血流灌注、抑制细胞凋亡，促进胰岛素分泌，有效延缓糖尿病患者胰岛素功能衰退的发展。此外，在糖尿病微血管和大血管病变的病理生理过程中，ACE2发挥抗ACE效应，调控心脏、视网膜和肾脏的缩、扩血管的平衡。ACE2及其激活剂、拮抗剂，可能在糖尿病及其并发症的防治领域具有极其广阔的临床应用前景。
Angiotensin-converting enzyme （ACE） 2 is a novel discovered mono-carboxypeptidase and the first homolog of ACE. It inhibits Ang Ⅱ signaling cascades mostly by cleaving Ang Ⅱ to generate Ang- （1-7） , which is mediated by the Mas receptor. The combined reduction in cell apoptosis and increment in islet blood flow caused by ACE2 could increase insulin secretion and preserve the islet function in diabetes. Besides,it is believed that ACE2 acts in a counter-regulatory manner to ACE in the pathogenesis of diabetic microvascular and macrovascular complications. The discovery of ACE2, its activator and antagonist may have considerable clinical value in the prevention and treatment of diabetes mellitus and its complications.
出处
《国际内分泌代谢杂志》
2010年第1期61-63,共3页
International Journal of Endocrinology and Metabolism
基金
国家重点基础研究发展计划（973）资助项目（2005CB523304）
